에방티바(ADR)(IVA)는 NAS에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $3.78 (+0.80%), 시가총액 $1.12B, 52주 범위 $2.98 ~ $7.15.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.
에방티바(ADR)의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 XTS에서 실시간으로 확인할 수 있습니다.
에방티바(ADR)의 현재 주가는 $3.78 (+0.80%)입니다. XTS에서 실시간 시세와 차트를 확인할 수 있습니다.
에방티바(ADR)의 시가총액은 약 $1.12B입니다.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH)…